NEWS HIGHLIGHTS
Published Studies Related to Atrovent HFA (Ipratropium)
Ipratropium bromide HFA. [2005] Ipratropium bromide is a nonselective antagonist of the muscarinic receptors located on airway smooth muscle, and is delivered via a metered-dose inhaler (MDI). Because of the requirement to phase out chlorofluorocarbon (CFC)-propelled MDIs, the ipratropium bromide inhalation aerosol MDI has been redesigned with a hydrofluoroalkane as the propellant (ipratropium bromide HFA)...
COPD patient satisfaction with ipratropium bromide/albuterol delivered via
Respimat: a randomized, controlled study. [2013] albuterol HFA (A) metered-dose inhalers as dual monotherapies (I + A)... CONCLUSION: CVT-R is an effective, environmentally friendly inhaler that provides
Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. [2010.02.01] Ipratropium bromide, an anticholinergic drug used for the treatment of asthma and chronic obstructive pulmonary disease, has low oral bioavailability, but systemic exposure, superior to oral administration, can be achieved by inhalation. Therefore, we investigated the pulmonary absorption mechanism of ipratropium using human bronchial epithelial BEAS-2B cells...
Clinical Trials Related to Atrovent HFA (Ipratropium)
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT� Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
The objective of this study was to determine the pharmacokinetic comparability of 84 µg
ipratropium bromide HFA-134a inhalation aerosol and 84 µg ATROVENT® CFC Inhalation Aerosol
in COPD patients
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes [Completed]
This will be a double-blind placebo-controlled study in which we plan to study 40
competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen
uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests
the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will
compare the athletes' airway response to the exercise challenge with and without the active
drug.
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg
once daily) and Atrovent® MDI (2 puffs of 20µg q. i.d.) among Filipino patients with COPD
Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients [Completed]
The objectives of this study are to assess the effect of salbutamol in comparison with
ipratropium bromide on the geometry of central and peripheral airways and to correlate
spirometric indices with the Computational Fluid Dynamics (CFD) based calculated airway
volumes and resistances for both compounds.
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease [Completed]
The objective of this study is to confirm that chronic dosing of 20 mcg and 40 mcg of
ipratropium bromide, administered via the RESPIMAT device, demonstrates clinical
comparability and similar safety profiles to the 36 mcg dose of ATROVENT® Inhalation Aerosol
(containing chlorinated fluorocarbons (CFC)) in patients with chronic obstructive pulmonary
disease (COPD). The efficacy and safety profiles of the two doses administered via the
RESPIMAT device will also be compared to their respective placebo groups
Reports of Suspected Atrovent HFA (Ipratropium) Side Effects
Death (3),
Dizziness (3),
Dyspnoea (3),
Dysgeusia (3),
Fear (2),
Oropharyngeal Pain (2),
Oral Discomfort (2),
Drug Effect Decreased (2),
Tremor (2),
Oral Pain (2), more >>
|